Synthesis
We reasoned that both the peracetylated (1 and 3) and the unprotected (2 and 4) derivatives could be prepared using the block coupling strategy. The N-terminal glycopeptide parts of the inhibitors could be synthesized employing solid phase peptide synthesis, and these peptides could then be condensed to the warhead. Subsequent deprotection should give glycosylated proteasome probes 1-4. For the on-resin synthesis of glycopeptides 11 and 12, suitably protected glycosylated serine analogues were S3 needed. Known Fmoc-Ser(OGlcNAc)-OH was synthesized in one step from Fmoc-Ser-OH and 2-acetylacetamido-3,4,6-tetra-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride as described in literature (Scheme 1). 1 The NMR-data of the obtained Fmoc-Ser(OGlcNAc)-OH was in accordance with the literature. LC-MS data however showed two peaks in a ratio of 1 to 1. 
Synthesis of proteasome probes 1-4
Proteasome probes 1-4 were synthesized as depicted in scheme 2. MBHA resin equipped with a HMPB linker 9 was loaded with FmocThr(OtBu)OH 10. Solid phase peptide synthesis followed by mild acidic cleavage from the resin afforded glycopeptides 11 and 12 which were directly used in a condensation with known warhead 13 3 . To this end, the tert-butoxycarbonyl protective group of 13 was removed with trifluoroacetic acid.
Peptides 11 and 12 were activated using HCTU in the presence of diisopropylethylamine (DiPEA), after which they were added to deprotected 13. Aqueous work-up followed by removal of the tert-butyl protective group of the threonine using 50% TFA in CH 2 Cl 2 gave crude proteasome probes 1 and 3. HPLC-purification allowed separation of the epimeric mixture, which was formed by the use of diastereomerically unpure Fmoc- TFA/CH 2 Cl 2 , 11: 84%, 12: 71%; (d) i) 13, HCTU, DiPEA; ii) 50% TFA/CH 2 Cl 2 , 1: 30%, 2: 26%; (e) NaOMe/MeOH, 3: 50%, 4: 41%.
The P5 position of probes 1-4 is sterically encumbered. To study the influence of the steric bulk on binding of the probe, probe 5 was synthesized (Scheme 3). In this probe, the carbohydrate core is replaced by a tyrosine residue. To this end, peptide 14 was synthesized on resin. Hydrazide 15 was obtained form peptide 14 by esterification with trimethysilyl diazomethane followed by treatment with hydrazine. The resulting
S6
hydrazide was converted to the corresponding acyl azide after which it was condensed with warhead 13. Removal of the protective groups gave probe 5 in good yield. ii) 50% TFA/CH 2 Cl 2 , 63%.
General Procedures:
All reagents were commercial grade and were used as received unless stated otherwise.
Biotine modified phosphine and NAG-thiazoline were synthesized as described. 4, 5 Building blocks 6 and 13 were synthesized using a modified literature procedure. 9, 170.5, 169.29, 169.26, 167.0, 92.1, 72.8, 72.1, 67.7, 61.6, 53.1, 52.5, 20.8, 20.6, 20.5 .
Fmoc-Ser(OGlcNAz)-OH (8)
Fmoc-Ser-OH 7 (247 mg, 0.75 mmol) and azidoacetylglucosamine 6 (325 mg, 0.75 mmol) were coevaporated with toluene (3×) before being dissolved in MeCN/CH 2 Cl 2 (11 mL, 2.5/3 v/v). Activated 3Å molecular sieves were added and the mixture was stirred for 30 min before it was cooled to 0°C. BF 3 . Et 2 O (171 μL) was added after which the reaction was stirred for 72h at room temperature. 6, 170.1, 169.3, 168.4, 156.2, 143.18, 143.15, 140.6, 127.0, 126.4, 124.3, 124.3, 119.2, 99.8, 71.5, 71.0, 68.4, 68.1, 66.4, 61.3, 53.6, 51.4, 46.4, 46.1, 19.46, 19.40 . 
Boc-Leucine epoxy ketone (13)
NaHCO 3 (11.76 g, 140 mmol) was dissolved in H 2 O (20 mL) and cooled to -10°C.
Trifluoroacetone (13.44 mL, 150 mmol) and (1-isobutyl-3-methyl-2-oxo-but-3-enyl)-carbamic acid tert-butyl ester 3 (5 mmol in 25 mL MeCN) were added followed by the portionwise addition of oxone (21.5 g, 35 mmol). The reaction was diluted with Et 2 O, extracted, the organic layer was dried (Na 2 SO 4 ) and concentrated in vacuo. Column chromatography (PE→ 8% EtOAc/PE) afforded warhead 13 (38%, 0.516 g, 1.9 mmol). and DiPEA (5 equiv.) in NMP was used to cap peptide 11. Peptides 12 and 14, which S11 contains an N-terminal azido acetyl, were capped with bromoacetyl bromide (5 equiv.) in the presence of DiPEA (10 equiv.) in NMP for 1h. The resin was washed and sodium azide (5 equiv.) in DMF was added followed by overnight shaking. The peptides were released from the resin by treatment with 1% TFA/CH 2 Cl 2 . An equal amount of toluene was added after which the volatiles were removed giving the crude peptides.
Ac-Ser(OGlcNAz)-Ile-Ile-Thr(OtBu)-OH (11)
Solid phase synthesis as described above afforded peptide 11 (84%, 0.758 g, 0.841 mmol 3, 173.5, 173.4, 173.0, 172.2, 172.1, 171.9, 171.7, 171.0, 170.3, 101.8, 73.8, 73.1, 69.9, 69.8, 69.4, 68.3, 63.2, 60.0, 59.5, 59.5, 59.2, 54.9, 54.4, 53.06, 53.01, 51.6, 40.4, 38.3, 38.0, 37.4, 26.1, 26.1, 25.8, 23.7, 22.5, 21.5, 20.8, 20.7, 20.7, 19.8, 17.0, 15.9, 15.8, 11.4, (neat)/cm -1 3288. 5, 2964.3, 2112.4, 1749.4, 1632.8, 1537.6, 1463.2, 1372.4, 1223.7 9, 170.8, 170.6, 169.9, 169.3, 169.2, 167.2, 100.3, 76.9, 73.9, 70.4, 70.3, 67.6, 66.3, 60.9, 58.6, 57.7, 56.9, 56.8, 55.2, 52.8, 51.4, 50.6, 49.1, 36.5, 36.4, 36.3, 24.2, 24.1, 23.0, 22.3, 20.9, 19.5, 16.3, 15.1, 15.0, 10.9, 10.88, 10.84 5, 172.4, 172.3, 171.8, 170.7, 168.3, 154.4, 131.8, 130.2, 124.7, 124.6, 124.5, 100.5, 79.1, 75.4, 67.4, 58.5, 58.4, 58.1, 57.4, 57.2, 54.4, 52.3, 38.1, 37.9, 37.3, 28.9, 28.4, 25.5, 25.3, 19.0, 15.6, 15.5, 11.5, 11.3 .
Az-Tyr-Ile-Ile-Thr-LeuEK (5)
Hydrazide 15 0, 172.7, 172.6, 172.2, 171.1, 168.5, 156.3, 130.6, 127.4, 115.8, 67.6, 59.6, 58.7, 58.6, 58.5, 55.0, 52.8, 52.4, 51.2, 39.7, 37.7, 37.5, 37.2, 25.6, 25.4, 25.3, 23.5, 21.3, 18.9, 16.9, 15.5, 15.5, 11.3, 
Competition experiment with MV151
To 9μL of human embryonic kidney 293 T (HEK) cell lysate (1 μg/μL in 50 mM Tris buffer pH 7.5, 250 mM sucrose, 5 mM MgCl 2 , 1 mM DTT, 2 mM ATP) was added 1 μL of a concentration series of probes 1-4 and the mixture was incubated for 1h at 37°C.
Next, 1 μL of MV151 (1 μM final concentration) was added and the solution was incubated for 1h at 37°C. The reaction was quenched by the addition of 4× Laemmli sample buffer (6 μL) containing β-mercaptoethanol followed by boiling for 3 min. The proteins were resolved on 12.5% SDS-PAGE. Fluorescence was measured in the wet gel slabs on a Typhoon Variable Mode Imager (Amersham Biosciences) using the CY3/Tamra settings (λ ex 532 λ em 560).
Labeling of the proteasome with probes 1-4
HEK-cell lysate (18μL, 1 μg/μL) was incubated with increasing concentrations of probes 1-4 (2 μL) for 1h at 37°C, after which biotine modified phosphine (2 μL, 400 μM final concentration) was added. After 1h at 37°C, the proteins were denatured by the addition S19 4× Laemmli sample buffer (6 μL) followed by boiling for 3 min. The proteins were resolved on 12.5% SDS-PAGE and transferred to a PVDF-membrane. The membranes were blocked with 0.5% bovine serum albumine in TBS-TWEEN ( 
Labeling of the proteasome with 1-4 in living cells
Human embryonic kidney cells ( 1×10 6 ) were cultured in 6-well plates in DMEM containing 10% fetal calf serum, 10 units/mL penicillin and 10 μg/mL streptomycin in a 7% CO 2 humidified incubator at 37°C overnight. The medium was withdrawn, the indicated amount probe 1-4 in DMSO (10 μL, 100× stock) was added to the medium (1 mL), after which the medium was added to cells. The cells were incubated for 16h with the probes. Thereafter, the medium was removed; the cells were washed with PBS and harvested. After flash freezing in N 2 (liquid), the cells were resuspended in 4 volumes of homogenation buffer (50 mM TRIS pH 7.5, 250 mM Sucrose, 5 mM MgCl 2 , 1 mM DTT, 2 mM ATP, 0.025% digitonin), sonicated (12W, 20 sec.) and centrifuged at 16.000 rcf at 4°C for 20 min. The supernatant was collected and the protein concentration was determined using Bradford analysis. In case of a competition experiment, some 10 μg of protein was exposed to MV151 (1 μM) for 1h at 37°C and subsequently treated as described previously for competition experiments in lysates. In case of a labeling S20 experiment, whole lysates (10 μg) were incubated with staudinger-bertozzi biotin phosphine reagent (400 μM) for 1h at 37°C and visualization as described before. 
